
Cajal Therapeutics is a Seattle-based biotechnology company dedicated to developing innovative medicines for serious diseases. Our team brings together deep expertise in genetics, computational biology, translational research, and drug development to advance therapies for diseases with high unmet need, including inflammatory anemias and neurodegeneration. 

Biotechnology

Cajal Therapeutics

CajalNeuro's headquarters in Seattle, WA, United States

Ian Peikon

Andrew Dervan

Robert Hershberg

Alex Vaughan

Ben Logsdon

Guy Breitenbucher

Mindy Stoffels

Valerie Huang

Niranjan Bose

Susan Hockfield

Rob Hershberg

Josh Wolfe

Tim Kutzkey

Martin Kampmann

Anthony Zador

Huda Zoghbi

Charles Zuker

Richard Hargreaves

Jay Shendure

David Holtzman

Martin Burke

The Research and Development team at CajalNeuro focuses on investigating the underlying mechanisms of neurodegenerative diseases through both experimental and computational approaches. They utilize advanced techniques in genomics, pharmacology, bioinformatics, and target validation to identify and develop potential therapeutic compounds. This multidisciplinary team works collaboratively to translate scientific discoveries into viable drug candidates, ultimately aiming to improve treatments for neurodegenerative conditions.

Research and Development

The Board Members at Cajal Neuroscience provide strategic oversight, governance, and high-level decision-making to guide the company's focus on drug discovery for neurodegenerative diseases. They influence key business directions, ensure financial sustainability, and support the executive leadership team in achieving long-term objectives.

Board Members

The Leadership Team at CajalNeuro is responsible for guiding the strategic direction and overall management of the company. They ensure alignment with the company’s mission to advance drug discovery for neurodegenerative diseases, and oversee key areas such as scientific research, corporate development, computational biology, and operational efficiency.

Leadership Team

The Corporate Development team at CajalNeuro is responsible for driving strategic initiatives, managing partnerships and alliances, overseeing procurement and financial operations, ensuring legal compliance, and fostering organizational growth to advance the company's mission in neurodegenerative drug discovery.

Corporate Development

The Software Development team at Cajal Neuroscience designs, develops, and maintains software systems to support drug discovery research for neurodegenerative diseases. This team ensures robust, scalable, and efficient solutions for data analysis, visualization, and computational biology needs, enhancing the overall research and development pipeline.

Software Development

This department provides expert guidance and counseling across various organizational functions.

Cajal Therapeutics

Org chart

Board & advisors

Teams

Research and Development

Board Members

Leadership Team

Corporate Development

Software Development

Advisory Services

Offices

Cajal Therapeutics

Org chart

Board & advisors

Teams

Research and Development

Board Members

Leadership Team

Corporate Development

Software Development

Advisory Services

Offices

Related companies